Paul Schechter

Dr. Schechter brings four decades of experience in translational medicine and drug development with proven success in advancing numerous drug candidates through development, clinical trials, and regulatory processes. His expertise extends from pharmaceutical development to clinical pharmacology and internal medicine. Following degrees from Columbia University and the University of Chicago, he trained in Internal Medicine at Rush Medical School and Georgetown University hospitals and in Clinical Pharmacology at the National Institutes of Health. Subsequently, he held major R&D executive positions at Merrell Dow Pharmaceuticals, Fujisawa, Hybridon, MacroChem, and Nucryst Pharmaceuticals. At Merrell Dow, he was responsible for the development and all clinical testing of DFMO, a component of Aminex’s AMXT 1501/DFMO therapy.